Creating "The future of the generics landscape"

Of all the drugs losing exclusivity in 2021 and beyond, how are the most potentially impactful drugs selected?

The future of the generics landscape

Of all the drugs losing exclusivity in 2021 and beyond, how are the most potentially impactful drugs selected?

Answering that question is both a science and an art. The data and analysis used to identify the Drugs to Watch drew from Clarivate life sciences solutions and integrated data sets that span the R&D and commercialization lifecycle as well as expert evaluation.

Scroll down to see how we do that or download the full report on PDF.

Download the generics landscape 2021

Timeline

To create an initial shortlist, we selected molecules losing exculsivity between 2021-2027 in key regions (United States, Europe [with focus on France, the United Kingdom, Germany, Spain and Italy], Japan) for analysis.

Learn more about the data

Ingredients

We included only single ingredients and excluded combination products.

Learn more about the analysis

Sales

We filtered the dataset according to total global or regional sales by molecule as well as by therapeutic area.

Learn more about the analytics

Context

Our experts then manually evaluated each drug in its individual context, based on factors such as global and regional sales, market share and trends, price evolution, generic activity, generic competitiveness and U.S. patent challenges.

Learn more about the analysis

Antineoplastic landscape

The future of the generics landscape also includes a special section on the antineoplastic landscape, which summarizes several brands expected to lose exclusivity during 2021-2026.

Download the generics landscape 2021

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team